Plus: air pollution and diabetes; more
Tuesday, March 23, 2021 : Issue #1117 |
|
Letter from the Editor
When a relative is diagnosed with diabetes, your first inclination is to throw everything at the disease and then see what works best. That especially is the case if they start insulin on day 1. It started with a long acting insulin, an SGLT-2, and a GLP-1. This worked well till meal time insulin was needed. Then when a C-peptide test was done and type 1 was diagnosed, the Endo said no more Trulicity or Farxiga, which didn’t make sense. The reason was given that those products were not indicated for type 1 patients.
It could be this is changing; our intern, George McDowell, from LECOM, has a new study on the use of GLP-1 agonists for type 1 patients.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
